Boujeke, E.J.; Catalan, A.; Arayan, L.; Mina, A.P.; James-McDonald, C.E.; Gupta, R.; Kulkarni, S.; Nasser, A.; Chowdhury, D.; Brackstone, M.;
et al. Real-World Toxicities and Outcomes of Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. Curr. Oncol. 2026, 33, 513.
https://doi.org/10.3390/curroncol33090513
AMA Style
Boujeke EJ, Catalan A, Arayan L, Mina AP, James-McDonald CE, Gupta R, Kulkarni S, Nasser A, Chowdhury D, Brackstone M,
et al. Real-World Toxicities and Outcomes of Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. Current Oncology. 2026; 33(9):513.
https://doi.org/10.3390/curroncol33090513
Chicago/Turabian Style
Boujeke, Emmanuel Joran, Aaron Catalan, Laurice Arayan, Alfred Patrick Mina, Christian Edward James-McDonald, Rasna Gupta, Swati Kulkarni, Abdullah Nasser, Deepro Chowdhury, Muriel Brackstone,
and et al. 2026. "Real-World Toxicities and Outcomes of Pembrolizumab in Early-Stage Triple-Negative Breast Cancer" Current Oncology 33, no. 9: 513.
https://doi.org/10.3390/curroncol33090513
APA Style
Boujeke, E. J., Catalan, A., Arayan, L., Mina, A. P., James-McDonald, C. E., Gupta, R., Kulkarni, S., Nasser, A., Chowdhury, D., Brackstone, M., Mathews, J., & Hamm, C.
(2026). Real-World Toxicities and Outcomes of Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. Current Oncology, 33(9), 513.
https://doi.org/10.3390/curroncol33090513
